A composition that helps to lubricate the intestines and promote bowel movements and its application
By combining fructooligosaccharides and curcumin, or by combining fructooligosaccharides, curcumin, galactooligosaccharides and oat β-glucan, a combination is formed to solve the problems of drug dependence and side effects of constipation, and to achieve the effects of lubricating the intestines, relieving constipation, and regulating the intestinal flora.
Patent Information
- Application Number
- CN202510521964.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-04-24
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2045-04-24
AI Technical Summary
Existing medications for constipation are addictive and have side effects, and gut microbiota imbalance is closely related to constipation. There is a lack of natural, safe, and effective combinations for regulation.
By rationally combining fructooligosaccharides and curcumin, or rationally combining fructooligosaccharides, curcumin, galactooligosaccharides and oat β-glucan, a composition can be formed for the purpose of lubricating the intestines and relieving constipation.
The composition can effectively improve constipation, shorten defecation time, increase intestinal transit rate, promote intestinal peristalsis, improve neurotransmitter and gastrointestinal hormone levels caused by constipation, regulate intestinal flora, and restore intestinal health.
Smart Images

Figure CN120392801B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of compositions, and particularly relates to a composition that helps to promote bowel movements and its application. Background Technology
[0002] Constipation is a common lower gastrointestinal dysfunction, mainly characterized by difficulty in defecation, a feeling of incomplete or obstructed bowel movements, fewer than three spontaneous bowel movements per week without the use of laxatives, and hard, dry stools. The main causes of slow transit constipation are usually related to damage to the smooth muscle of the colon or dysfunction of its enteric nerves. Constipation not only causes physical discomfort such as bloating, vomiting, intestinal obstruction, and perforation, but also increases the risk of anxiety and irritability, thus affecting an individual's quality of life and triggering varying degrees of psychological distress.
[0003] Serotonin (5-HT) is a neurotransmitter, with over 95% secreted by enterochromaffin cells. By binding to its receptors, 5-HT promotes intestinal motility and plays a crucial role in intestinal movement and secretion. The serotonin transporter (SERT) is a transmembrane transporter responsible for reuptake of excess extracellular 5-HT, terminating its physiological effects and regulating extracellular 5-HT availability. Studies have found that the gut microbiota can regulate serotonergic signaling by modulating SERT expression. Imbalances in the gut microbiota may cause abnormal SERT expression, thereby slowing intestinal motility and promoting constipation. Prebiotics are dietary components that selectively promote the growth of beneficial bacteria in the gut. In the colon, they are fermented by beneficial bacteria to produce large amounts of short-chain fatty acids (SCFAs). Research shows that SCFAs play an important role in improving intestinal motility, increasing intestinal water absorption, and regulating intestinal pH, and have a significant effect on relieving constipation.
[0004] Conventional clinical treatment for constipation primarily relies on medication, including osmotic laxatives such as lactulose and polyethylene glycol, stimulant laxatives such as diclofenac and senna, stool softeners such as mineral oil, and 5-HT4 receptor agonists such as mosapride and procapapride. Drug treatment is prone to dependence and is accompanied by adverse reactions such as headache, nausea, abdominal pain, and diarrhea. Studies have shown that constipation is closely related to gut microbiota imbalance. Therefore, finding natural, effective, and safe combinations to treat constipation by reducing the side effects of traditional drugs and addressing constipation from multiple perspectives, including gut microbiota regulation, has become an urgent problem to be solved. Summary of the Invention
[0005] To address the shortcomings of existing technologies, this invention aims to propose a composition that promotes bowel movement and its application. By rationally combining fructooligosaccharides and curcumin, or rationally combining fructooligosaccharides, curcumin, galactooligosaccharides, and oat β-glucan, a good bowel-regulating effect is achieved. This composition combines functionality and nutrition, showing broad application prospects in promoting bowel movement and improving constipation.
[0006] To achieve the above objectives, on the one hand, the present invention provides a composition that helps to lubricate the intestines and promote bowel movements. The composition includes fructooligosaccharides and curcumin, wherein the mass ratio of fructooligosaccharides to curcumin is 40-70:3-10, for example 70:4, 60:3, 50:5, or 40:10.
[0007] Furthermore, the mass ratio of the oligofructose to curcumin is 10:1.
[0008] Secondly, the present invention provides a composition that helps to lubricate the intestines and promote bowel movements. The composition includes fructooligosaccharides, curcumin, galactooligosaccharides, and oat β-glucan, wherein the mass ratio of fructooligosaccharides, curcumin, galactooligosaccharides, and oat β-glucan is 40-70:3-10:10-35:5-18, for example 70:4:10:6, 60:3:15:12, 50:5:25:10, 40:10:35:5, 50:5:17:18, and 50:5:20:15.
[0009] Furthermore, the mass ratio of the fructooligosaccharides, curcumin, galactooligosaccharides, and oat β-glucan is 10:1:5:2.
[0010] Thirdly, the present invention provides a product comprising the composition described in the first or second aspect.
[0011] Furthermore, the product is a health food or a medicine, and the product also includes excipients acceptable to health foods or medicines.
[0012] Fourthly, the present invention provides the use of the composition described in the first or second aspect in the preparation of a product capable of relieving constipation, wherein the product is a health food or a medicine.
[0013] Furthermore, the application is in the preparation of products that can improve constipation, promote intestinal peristalsis and / or increase intestinal transit rate.
[0014] Furthermore, the constipation described is slow transit constipation.
[0015] Furthermore, the application includes at least one of the following: (1) Application in the preparation of products that can shorten defecation time for patients with constipation; (2) Application in the preparation of products that can improve the release of constipation-related neurotransmitters and gastrointestinal hormones; (3) Application in the preparation of products that can improve intestinal flora imbalance caused by constipation; (4) Application in the preparation of products that can improve intestinal barrier damage caused by constipation Furthermore, the use of the product for improving the release of constipation-related neurotransmitters and gastrointestinal hormones includes at least one of the following: (1) Application in the preparation of products that can improve the decrease in 5-HT and SP levels caused by constipation; (2) Application in the preparation of products that can improve the increase in VIP levels caused by constipation; (3) Application in the preparation of products that can improve the decline in Gas and MTL levels caused by constipation.
[0016] Compared with the prior art, the present invention has the following advantages: (1) This invention demonstrates that the combined intervention of fructooligosaccharides and curcumin can help improve constipation and has a synergistic effect.
[0017] (2) This invention demonstrates that the combined intervention of fructooligosaccharides, curcumin, galactooligosaccharides and oat β-glucan can help improve constipation and has a synergistic effect.
[0018] (2) The composition of the present invention can effectively improve constipation, shorten the defecation time of constipated patients, increase the intestinal transit rate, and promote intestinal peristalsis; it can improve the decrease in 5-HT, SP, Gas and MTL levels caused by constipation and improve the increase in VIP levels caused by constipation; it can improve the intestinal flora imbalance caused by constipation and improve the intestinal barrier damage caused by constipation, and has multiple functional effects on lubricating the intestines and relieving constipation. Attached Figure Description
[0019] Figure 1 The figure shows the effect of the composition of the present invention on the defecation of mice. In the figure, A is the time of the first black stool, B is the fecal weight at 5 h, C is the number of fecal particles at 5 h, and D is the fecal water content. Different lowercase letters in the figure indicate significant differences between groups (p < 0.05).
[0020] Figure 2 The figure shows the effect of the composition of the present invention on the ink propulsion rate of mice.
[0021] Figure 3The figure shows the effect of the composition of the present invention on serum neurotransmitters and hormones in mice. A represents the level of 5-hydroxytryptamine (5-HT), B represents the level of substance P (SP), C represents the level of vasoactive intestinal peptide (VIP), D represents the level of motilin (MTL), and E represents the level of gastrin (Gas).
[0022] Figure 4 The effect of composition III on the α-diversity of mouse gut microbiota is shown, where A is the Ace index and B is the Simpson index.
[0023] Figure 5 The effect of the composition on the β-diversity of the intestinal flora in mice.
[0024] Figure 6 The figure shows the effect of the composition on the phylum-level composition of the intestinal flora in mice.
[0025] Figure 7 The figure shows the effect of the composition on the gut microbiota composition of mice at the genus level.
[0026] Figure 8 The figure shows the effect of the composition on the level of short-chain fatty acids in mouse feces. Detailed Implementation
[0027] The following detailed embodiments further illustrate the concept and technical effects of the present invention to fully understand its purpose, features, and effects. Unless otherwise specified, all methods described are conventional methods. Unless otherwise specified, all materials are available from publicly available commercial sources. The illustrative embodiments and descriptions of the present invention are used to explain the invention and do not constitute an undue limitation thereof. It should be noted that, unless otherwise specified, the embodiments and features described in the present invention can be combined with each other.
[0028] In the examples, fructooligosaccharides were purchased from Shandong Bailong Chuangyuan Biotechnology Co., Ltd., galactooligosaccharides were purchased from Shandong Bailong Chuangyuan Biotechnology Co., Ltd., curcumin was purchased from Sigma-Aldrich, oat β-glucan was purchased from Xi'an Zhongyan Kangze Biotechnology Co., Ltd., and aloe vera gel freeze-dried powder was purchased from Shaanxi Baichuan Biotechnology Co., Ltd.
[0029] Example 1: Screening of raw materials for the composition 5-HT, as an important neurotransmitter in the gut-brain axis, plays a crucial role in regulating intestinal motility. SERT is a key protein regulating extracellular 5-HT availability. This invention uses SERT mRNA expression levels to characterize the potential activity of various substances in improving constipation. The specific steps are as follows: Each test substance was dissolved in DMEM complete medium (containing 10% fetal bovine serum and 1% penicillin-streptomycin) and filtered through a 0.22 µm sterile syringe to prepare solutions with concentrations ranging from 1 to 200 mg / mL. IEC-6 cells were seeded at a density of 5 × 10⁵ / mL in 6-well plates and cultured overnight at 37 °C with 5% CO₂ for 4 days. The cell culture medium was changed on the second day after seeding. Before intervention with the test substances, the cells were serum starved for 1 h in serum-free DMEM medium, followed by 24 h of culture with 3 mL of different concentrations of the test substance. The blank control group continued to be cultured in DMEM complete medium. After the intervention, the medium in the 6-well plates was discarded, and 1 mL of Trizol was added to each well. The solution from each well was then transferred to a 1.5 mL Eppendorf tube. Add 200 μL of chloroform, shake until the solution turns a homogeneous milky white, centrifuge at 12000 rpm for 15 min at 4 ℃, transfer the upper aqueous phase to another clean centrifuge tube, add an equal volume of isopropanol and mix by inverting, let stand at room temperature for 30 min, then centrifuge at 12000 rpm for 15 min at 4 ℃. Discard the supernatant, add 1 mL of 75% ethanol (prepared with DEPC water) pre-cooled at -20 ℃ to wash the precipitate (the precipitate should be white); centrifuge at 5000 rpm for 5 min at 4 ℃, carefully discard the supernatant, dry the precipitate and dissolve it in 30 μL of DEPC water, then freeze at -80 ℃.
[0030] Transfer 10 μL of RNA to a 200 μL enzyme-free EP tube, add 4 μL of 5×All-In-One RT MasterMix and 6 μL of Nuclease-free H2O. After brief centrifugation using a handheld centrifuge, synthesize cDNA according to the following program: 25 ℃, 10 min; 42 ℃, 50 min; 85 ℃, 5 min. Mix 1 μL of cDNA, 0.2 μL of upstream primer, 0.2 μL of downstream primer, 10 μL of SYBR® Premix Ex Taq™, and 8.6 μL of sterile water in an eight-tube set. Set the program as follows: pre-denaturation at 95 ℃ for 180 s, amplification at 95 ℃ for 30 s, 60 ℃ for 30 s, and 72 ℃ for 30 s, for 40 cycles. Perform PCR amplification using GAPDH as an internal control.
[0031] The mRNA expression level of the blank control group was taken as 1, and the ratio of the mRNA expression level of each intervention group to the mRNA expression level of the blank control group was taken as the final result.
[0032] As shown in Table 1, fructooligosaccharides, galactooligosaccharides, curcumin, oat β-glucan, and aloe vera gel lyophilized powder all have the activity of downregulating the relative expression level of SERT mRNA.
[0033] Taking into account factors such as the bioactivity, economic cost, sensory characteristics, safety, sustainability, eco-friendliness, social responsibility, recommended intake, and processing methods of the raw materials, fructooligosaccharides, galactooligosaccharides, oat β-glucan, and curcumin were selected as raw materials for subsequent composition formulation research.
[0034] Table 1. Effects of formulation ingredients on relative SERT mRNA expression levels
[0035] Example 2: Effect of the composition on the relative expression level of SERT mRNA Weigh each ingredient according to the following formula, and mix the ingredients in a double helix conical mixer for 15-30 minutes to obtain the composition.
[0036] Composition I Ingredients: 70 g fructooligosaccharides, 4 g curcumin, 10 g galactooligosaccharides, 6 g oat β-glucan; Composition II ingredients: 60 g fructooligosaccharides, 3 g curcumin, 15 g galactooligosaccharides, 12 g oat β-glucan; Composition III Ingredients: 50 g fructooligosaccharides, 5 g curcumin, 25 g galactooligosaccharides, 10 g oat β-glucan; Composition IV ingredients: 40 g fructooligosaccharides, 10 g curcumin, 35 g galactooligosaccharides, and 5 g oat β-glucan; Composition V Ingredients: 50 g fructooligosaccharides, 5 g curcumin, 17 g galactooligosaccharides, 18 g oat β-glucan; Composition VI Ingredients: 50 g fructooligosaccharides, 5 g curcumin, 20 g galactooligosaccharides, 15 g oat β-glucan; Composition VII Ingredients: 81.81 g of fructooligosaccharides, 8.18 g of curcumin; Comparative Example 1 Ingredients: 90 g of fructooligosaccharides; Comparative Example 2 Ingredients: Curcumin 90 g; Comparative Example 3 Ingredients: 90 g of galacto-oligosaccharides; Comparative Example 4 Ingredients: 90 g of oat β-glucan.
[0037] The effects of compositions I-VII and comparative examples 1-4 on the relative expression levels of SERT mRNA were determined using the method described in Example 1 to characterize the potential effect of each composition on improving constipation.
[0038] Table 2. Effects of the composition on the relative expression level of SERT mRNA
[0039] Example 3: The effect of the composition on improving constipation in mice.
[0040] 1. Experimental Design and Grouping Six-week-old SPF-grade male BALB / c mice (weighing 18-22g) were selected and housed in an environment with a temperature of 20±2℃, relative humidity of 65±5%, a light-dark cycle of 12 h, and good ventilation. The mice were fed pellets and had free access to water. Before the experiment, the mice were housed for one week to acclimatize. The mice were randomly divided into a blank control group, a model group, a low-formula group, a medium-formula group, a high-formula group, a combination group I, a combination group II, a combination group IV, a combination group V, a combination group VI, a combination group VII, a comparative example group 1, a comparative example group 2, a comparative example group 3, a comparative example group 4, and a positive control group (n=10), and fed as follows: Blank control group: normal saline was administered by gavage on days 1-14; normal saline was administered by gavage first on days 15-28, followed by normal saline 1 hour later.
[0041] Model group: LOP (10 mg / kg BW) was administered by gavage on days 1-14; LOP (10 mg / kg BW) was administered by gavage first on days 15-28, followed by normal saline by gavage 1 hour later.
[0042] Low-formulation group: LOP (10 mg / kg BW) was administered by gavage on days 1-14; LOP (10 mg / kg BW) was administered by gavage first on days 15-28, followed by low-dose combination III (37 mg / kg BW) 1 hour later.
[0043] Medium-formulation group: LOP (10 mg / kg BW) was administered by gavage on days 1-14; LOP (10 mg / kg BW) was administered by gavage first on days 15-28, followed by medium-dose combination III (74 mg / kg BW) 1 hour later.
[0044] High-formulation group: LOP (10 mg / kg BW) was administered by gavage on days 1-14; LOP (10 mg / kg BW) was administered by gavage first on days 15-28, followed by high-dose combination III (148 mg / kg BW) 1 hour later.
[0045] Composition I: LOP (10 mg / kg BW) was administered by gavage on days 1-14; LOP (10 mg / kg BW) was administered by gavage first on days 15-28, followed by Composition I (74 mg / kg BW) 1 hour later.
[0046] Group II: LOP (10 mg / kg BW) was administered by gavage on days 1-14; LOP (10 mg / kg BW) was administered by gavage first on days 15-28, followed by Group II (74 mg / kg BW) 1 hour later.
[0047] Composition IV group: LOP (10 mg / kg BW) was administered by gavage on days 1-14; LOP (10 mg / kg BW) was administered by gavage first on days 15-28, followed by composition IV (74 mg / kg BW) 1 hour later.
[0048] Composition V: LOP (10 mg / kg BW) was administered by gavage on days 1-14; LOP (10 mg / kg BW) was administered by gavage first on days 15-28, followed by composition V (74 mg / kg BW) 1 hour later.
[0049] Group VI of Composition: LOP (10 mg / kg BW) was administered by gavage on days 1-14; LOP (10 mg / kg BW) was administered by gavage first on days 15-28, followed by Composition VI (74 mg / kg BW) 1 hour later.
[0050] Composition VII: LOP (10 mg / kg BW) was administered by gavage on days 1-14; LOP (10 mg / kg BW) was administered by gavage first on days 15-28, followed by composition VII (74 mg / kg BW) 1 hour later.
[0051] Comparative Group 1: LOP (10 mg / kg BW) was administered by gavage on days 1-14; LOP (10 mg / kg BW) was administered by gavage first on days 15-28, followed by fructooligosaccharide (74 mg / kg BW) 1 hour later.
[0052] Comparative Group 2: LOP (10 mg / kg BW) was administered by gavage on days 1-14; LOP (10 mg / kg BW) was administered by gavage first on days 15-28, followed by curcumin (74 mg / kg BW) 1 hour later.
[0053] Comparative group 3: LOP (10 mg / kg BW) was administered by gavage on days 1-14; LOP (10 mg / kg BW) was administered by gavage first on days 15-28, followed by galactooligosaccharide (74 mg / kg BW) 1 hour later.
[0054] Comparative group 4: LOP (10 mg / kg BW) was administered by gavage on days 1-14; LOP (10 mg / kg BW) was administered by gavage first on days 15-28, followed by oat β-glucan (74 mg / kg BW) 1 hour later.
[0055] Positive drug group: LOP (10 mg / kg BW) was administered by gavage on days 1-14; LOP (10 mg / kg BW) was administered by gavage first on days 15-28, followed by polyethylene glycol 4000 (3 g / kg BW) by gavage 1 hour later.
[0056] 2. Mouse fecal parameter measurement experiment After gavage on day 28, mouse feces were collected and stored at -80℃. Mice were fasted but allowed free access to water for 16 hours. Fecal parameters were measured on day 29: the blank control group received saline, while the model group, low-formula group, medium-formula group, high-formula group, combination I group, combination II group, combination IV group, combination V group, combination VI group, combination VII group, comparative example 1 group, comparative example 2 group, comparative example 3 group, comparative example 4 group, and positive control group received LOP (10 mg / kg BW) via gavage. 0.5 hours later, mice in the blank control group and model group were gavage with ink (0.2 mL), while the low-formula group, medium-formula group, high-formula group, combination I group, combination II group, combination IV group, combination V group, combination VI group, combination VII group, comparative example 1 group, comparative example 2 group, comparative example 3 group, comparative example 4 group, and positive control group received ink containing the corresponding test sample (0.2 mL). All animals were housed individually and provided with normal drinking water and food. Starting from the time the mice were injected with ink, the time of their first black feces, the number and weight of black feces excreted within 5 hours were recorded, and the water content of the mice's feces was measured.
[0057] The feces were placed into centrifuge tubes of known weight, and the wet weight of the feces was measured and calculated. The centrifuge tubes containing the feces were then placed in a vacuum freeze dryer. After drying, the dry weight of the feces was measured, and the moisture content of the feces was calculated. Fecal moisture content (%) = (Fecal wet weight - Fecal dry weight) / Fecal wet weight × 100% The time to first black stool, weight of black stool at 5 hours, number of black stool particles, and fecal water content were used as indicators to evaluate constipation in mice and its improvement. Figure 1 As shown in Figure A, the time to first black stool in the blank control group was 46.5 ± 1.46 min, while the time to first black stool in the model group reached 132.33 ± 3.89 min, indicating a significant increase in the time to first black stool. This demonstrates the successful establishment of a constipation mouse model after LOP modeling. Compared to the model group, the time to first black stool in both the formulation group and the positive control group was significantly reduced. Specifically, the times to first black stool in the medium- and high-formulation groups were 69.5 ± 2.10 min and 62 ± 3.00 min, respectively, showing no significant difference from the blank control group. This indicates that the composition can promote intestinal peristalsis and improve constipation.
[0058] like Figure 1 B Figure 1 C and Figure 1 As shown in Figure D, compared with the blank control group, the mass and quantity of black stool and the water content of feces in the model group mice were significantly reduced within 5 hours. Compared with the model group, the mass and quantity of black stool and the water content of feces in the low-formula group, medium-formula group, high-formula group and positive drug group were significantly increased within 5 hours. The results indicate that feeding the formula combination can shorten the defecation time, increase the amount of stool, and increase the water content of feces, thereby effectively relieving constipation.
[0059] 3. Mouse small intestinal motility test After day 29 of the experiment, the mice were fasted but allowed free access to water for 16 hours. The intestinal propulsion rate of the mice was measured on day 30.
[0060] The blank control group was administered physiological saline by gavage. The model group, low-formula group, medium-formula group, high-formula group, combination group I, combination group II, combination group IV, combination group V, combination group VI, combination group VII, comparative example 1, comparative example 2, comparative example 3, comparative example 4, and positive drug group were administered LOP (10 mg / kg BW) by gavage. After 0.5 h, the blank control group and model group mice were administered ink by gavage (0.2 mL), while the low-formula group, medium-formula group, high-formula group, combination group I, combination group II, combination group IV, combination group V, combination group VI, combination group VII, comparative example 1, comparative example 2, comparative example 3, comparative example 4, and positive drug group were administered ink containing the corresponding test sample by gavage (0.2 mL). All animals were housed individually and provided normal drinking water and food. After 25 minutes, the animal was euthanized, the abdominal cavity was opened, the mesentery was separated, and the intestinal segment from the upper end of the pylorus to the lower end of the ileocecal junction was cut off. The segment was placed on graph paper, and the small intestine was gently pulled into a straight line. The length of the segment was measured as the "total length of the small intestine", and the length from the pylorus to the leading edge of the ink was measured as the "ink propulsion length".
[0061] Ink propulsion rate (%) = Ink propulsion length (cm) / Total small intestine length (cm) × 100% The ink propulsion rate of mice in each group was measured, and the results are as follows: Figure 2 As shown in the figure. Compared with the blank control group, the ink propulsion rate of mice in the model group was significantly reduced; compared with the model group, the ink propulsion rate of mice in the low-formula group, medium-formula group, high-formula group, and positive drug group was significantly increased, with medium and high doses of the formulation showing the best effects. Compared with the low, medium, and high formulation groups and each combination group, the effect of comparative example 1, comparative example 2, comparative example 3, and comparative example 4 on increasing the ink propulsion rate of mice was significantly weakened, indicating that the combination of fructooligosaccharide and curcumin, and the combination of fructooligosaccharide, curcumin, galactooligosaccharide, and oat β-glucan had a better intervention effect on constipation than the intervention effect of single-component substances at the same dose. The above results demonstrate that there is a synergistic effect between fructooligosaccharide and curcumin in improving constipation, and there is also a synergistic effect between fructooligosaccharide, curcumin, galactooligosaccharide, and oat β-glucan in improving constipation.
[0062] Example 4: Effects of the composition on serum neurotransmitters and hormones in constipated mice Neurotransmitters such as serotonin (5-HT), substance P (SP), and vasoactive intestinal peptide (VIP) directly affect intestinal peristalsis by regulating intestinal smooth muscle contraction and intestinal secretion. Meanwhile, gastrointestinal hormones such as motilin (MTL) and gastrin (Gas) play an important role in regulating gastrointestinal motility by regulating gastrointestinal smooth muscle contraction.
[0063] The experimental animals were grouped as in Example 3. The levels of 5-HT, SP, VIP, MTL, and Gas in mouse serum were measured using a commercial ELISA kit. The results are as follows: Figure 3 As shown in the figure. Compared with the blank control group, after LOP modeling, the serum 5-HT and SP levels of mice in the model group were significantly decreased, the VIP level was significantly increased, and the MTL and Gas levels were significantly decreased. Compared with the model group, the serum 5-HT and SP levels of mice in the low-formula group, medium-formula group, high-formula group, and positive drug group were significantly increased, the VIP level was significantly decreased, and the MTL and Gas levels were significantly increased. After intervention in constipated mice, the formulation groups reduced the level of the inhibitory neurotransmitter VIP and increased the levels of the excitatory neurotransmitters 5-HT and SP, promoted intestinal peristalsis, and effectively improved constipation.
[0064] Example 5: Effect of the composition on gut microbiota diversity in constipated mice The experimental animals were grouped as in Example 3. To investigate the effect of the composition on the diversity and richness of the gut microbiota in constipated mice, the α-diversity of the mouse gut microbiota was analyzed, and the results are as follows: Figure 4 As shown in the figure. The Ace index reflects the richness of the gut microbiota; a higher Ace index indicates a richer gut microbiota. The Simpson index reflects the diversity of the gut microbiota; a lower Simpson index indicates a more diverse gut microbiota. Compared with the blank control group, the Ace index of the model group mice was significantly lower (p<0.05), and the Simpson index was significantly higher (p<0.05), indicating that constipation significantly reduced the richness and diversity of the gut microbiota. Compared with the model group, the Ace index of the formulation group (hereinafter, "formulation group" refers to the "medium-formulation group") was higher (p<0.05), and the Simpson index was significantly lower (p<0.05), with no significant difference from the positive drug group (p>0.05), indicating that the formulation can effectively restore the α-diversity of the gut microbiota in mice and improve the gut microbiota in constipated mice.
[0065] β-diversity can assess differences in microbial communities among different groups, and the results are as follows: Figure 5As shown in the figure, principal component analysis (PCA) based on OUT reveals significant clustering of gut microbiota composition among different groups of mice. The groups are clearly distinguishable along the PC1 axis, indicating differences in gut microbiota composition among the groups. The blank control group and model group formed independent clusters, while the gut microbiota distribution of the formulation group and positive drug group approached that of the blank control group, suggesting that this composition can significantly improve the microbiota structure shift caused by constipation.
[0066] Example 6 Effect of the composition on the species composition of the gut microbiota in constipated mice The experimental animals were grouped as in Example 3. The phylum-level composition of the gut microbiota in each group of mice is as follows: Figure 6 As shown, the gut microbiota of the four groups of mice mainly consisted of Bacteroidota (Bacteroidetes) and Fimicutes Composition of Firmicutes (phylum), studies have shown... Bacteroidota Decreased abundance of Bacteroidetes is an important microbial marker of constipation. Compared with the blank control group, the model group mice... Bacteroidota The relative abundance of Bacteroidetes was significantly reduced (p<0.05) after gavage in the positive drug group. Bacteroidota The relative abundance of Bacteroidetes was significantly increased (p<0.05), and there was no significant difference between the formulation group and the positive control group (p>0.05). Compared with the blank control group, the model group mice... Fimicutes The relative abundance of Firmicutes was significantly increased compared to the model group. The abundance of Firmicutes in the formulation group and the positive drug group was significantly higher than that in the model group. Fimicutes The relative abundance of Firmicutes was significantly reduced (p<0.05). Compared with the model group, the formulation group... Actinobacteriota The relative abundance of Actinobacteria was significantly increased (p<0.05). Compared to the blank control group, the model group mice showed significantly higher abundance. Proteobacteria The abundance of Proteobacteria was significantly increased (p<0.05), suggesting a possible abnormal increase in the abundance of pathogenic bacteria. After intervention, compared with the model group, the abundance of pathogenic bacteria in the formulation group and the positive drug group was significantly increased. Proteobacteria The abundance of (Proteobacteria) decreased significantly (p<0.05), with no significant difference compared to the blank control group (p>0.05), inhibiting... Proteobacteria Proliferation of pathogenic bacteria such as Proteobacteria.
[0067] The composition of the gut microbiota at the genus level in each group of mice is as follows: Figure 7 As shown, compared with the blank control group, the model group (LOP) mice norank_o_Clostridia_UCG-014 The relative abundance of (Unclassified Clostridium perfringens-UCG-014) increased significantly. Bacteroides (Bacteroides) Ruminococcus (Ruminococcus) and Alistipes The relative abundance of *Alternaria* was significantly reduced (p<0.05). Compared with the model group, the formulation group mice... norank_o_Clostridia_UCG-014 The relative abundance of *Clostridium unclassified*-UCG-014 was significantly decreased (p<0.05), and there was no significant difference between the formulation group and the positive control group. Compared with the model group, mice in the positive control group... Ruminococcus The relative abundance of *Ruminococcus* spp. was significantly increased (p<0.05) in mice in the formulation group. Ruminococcus The relative abundance of *Ruminococcus* spp. also increased significantly, and the recovery effect was significantly better than that of the positive drug group (p<0.05). Studies have shown that the gut microbiota... Clostridia UCG-014 Increased relative abundance may lead to inflammation in the body. Increased pro-inflammatory factors can reduce the synthesis of 5-HT and decrease the bioavailability of 5-HT. Bacteroidota Bacteroidetes are one of the core gut microbiota, capable of efficiently breaking down dietary fiber and complex polysaccharides to produce short-chain fatty acids (SCFAs). SCFAs can promote the synthesis and release of 5-HT by enterochromaffin cells (EC cells), and also enhance the excitability of enteric neurons, promote intestinal peristalsis, and improve constipation. Bacteroides (Bacteroides) Ruminococcus (Ruminococcus) and Alistipes All of the bacteria in the genus *Alternaria* produce short-chain fatty acids, which can improve constipation.
[0068] Short-chain fatty acids (SCFAs) are metabolic products of gut microbiota. They not only provide essential nutrients and energy for intestinal epithelial cells but also promote the growth and reproduction of beneficial bacteria while inhibiting the excessive proliferation of harmful bacteria. Furthermore, they promote intestinal peristalsis, playing a crucial role in maintaining gut health. The content of SCFAs in the feces of mice in each group was measured, and the results are as follows: Figure 8 As shown, compared with the blank control group, the levels of total acid, acetic acid, propionic acid, and butyric acid in the feces of mice in the model group were significantly reduced. Compared with the model group, the formulation group and the positive drug group significantly increased the levels of total acid, propionic acid, and butyric acid in the feces of mice, and the levels of total acid, propionic acid, and butyric acid in the formulation group were significantly higher than those in the positive drug group. The above results indicate that the formulation composition can effectively increase the content of short-chain fatty acids in the feces of mice, which is beneficial to intestinal health.
[0069] This invention demonstrates, through experiments measuring the time to first black stool, ink propulsion rate, and fecal water content, that the composition can shorten defecation time and promote intestinal peristalsis in mice. PCR showed that the composition can downregulate SERT mRNA expression levels in IEC-6 cells. Simultaneously, the levels of 5-hydroxytryptamine (5-HT), substance P (SP), vasoactive intestinal peptide (VIP), motilin (MTL), and gastrin (Gas) in mouse serum were detected, demonstrating that the composition can promote the release of constipation-related neurotransmitters and gastrointestinal hormones. Furthermore, analysis of mouse intestinal flora and determination of short-chain fatty acid content using gas chromatography-mass spectrometry demonstrated that the composition can regulate intestinal flora, increase its diversity and richness, and improve short-chain fatty acid levels, thus contributing to maintaining intestinal homeostasis.
[0070] The embodiments described above are only some embodiments of the present invention, not all embodiments. Other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are all within the scope of protection of the present invention.
Claims
1. A composition that helps to lubricate the intestines and promote bowel movements, characterized in that, The composition comprises fructooligosaccharides, curcumin, galactooligosaccharides, and oat β-glucan, wherein the mass ratio of fructooligosaccharides, curcumin, galactooligosaccharides, and oat β-glucan is 10:1:5:
2.
2. The composition according to claim 1, characterized in that, The preparation method of the combination includes the steps of weighing fructooligosaccharides, curcumin, galactooligosaccharides and oat β-glucan, and mixing them.
3. A product characterized in that, The product includes the composition according to claim 1 or 2; the product is a health food or a medicine, and the product also includes excipients acceptable to health foods or medicines.
4. The use of the composition according to claim 1 or 2 in the preparation of a product capable of lubricating the intestines and relieving constipation, characterized in that, The product is either a health food or a medicine.
5. The application according to claim 4, characterized in that, The application is in the preparation of products that can improve constipation, promote intestinal peristalsis and / or increase intestinal transit rate.
6. The application according to claim 4, characterized in that, The application includes at least one of the following: (1) Application in the preparation of products that can shorten defecation time for patients with constipation; (2) Application in the preparation of products that can improve the release of constipation-related neurotransmitters and gastrointestinal hormones; (3) Application in the preparation of products that can improve intestinal flora imbalance caused by constipation; (4) Application in the preparation of products that can improve intestinal barrier damage caused by constipation.
7. The application according to claim 6, characterized in that, The use of products that improve the release of constipation-related neurotransmitters and gastrointestinal hormones includes at least one of the following: (1) Application in the preparation of products that can improve the decrease in 5-HT and SP levels caused by constipation; (2) Application in the preparation of products that can improve the increase in VIP levels caused by constipation; (3) Application in the preparation of products that can improve the decline in Gas and MTL levels caused by constipation.
Citation Information
Patent Citations
Composite prebiotics and preparation method thereof
CN106418483A
Water-soluble curcumin oligosaccharide compound and preparation method for solid beverage thereof
CN109674054A
Health-care composition containing microbial beneficial bacteria and preparation method of health-care composition
CN119817818A
